Heidelberg start-up develops system for precise drug monitoring with just one drop of blood
Start-up portrait: QuantiLight revolutionizes blood tests with home monitoring platform
Millions of patients with chronic diseases require regular blood tests to adjust their medication dosage - a process that previously required time-consuming visits to hospitals or laboratories. Heidelberg-based start-up QuantiLight has developed an innovative solution that fundamentally changes this process: a portable blood testing platform that allows patients to monitor their medication levels from the comfort of their own home.
Innovative technology with easy handling
QuantiLight's core product is based on a patented sensor technology that can quantify biomarkers and drug concentrations in complex matrices with impressive precision. These bioluminescent sensors emit light that changes color depending on the concentration of the biomarker. Even at very low analyte concentrations in the nanomolar range, they can be easily detected with simple equipment such as a digital camera.
The system consists of three main components: a test cartridge, a handheld reader and a mobile app. The test only requires a drop of blood (5 μl) from a finger prick, which is applied to the test cartridge. The handheld reader analyzes the blood sample using proprietary technology and sends the results to the mobile app via Bluetooth. Within just 15 minutes, patients receive the result of their current medication concentration and can make adjustments in consultation with their doctor if necessary.
From the Max Planck Institute to a promising start-up
QuantiLight has its roots in the Department of Chemical Biology at the Max Planck Institute for Medical Research. The founding team combines in-depth technological understanding with practical implementation experience to bring innovations to where they matter most - to the patients.
The company is headed by CEO Corentin Gondrand, who has a doctorate in chemical biology. Estelle Bonedeau with a PhD in Molecular Biology serves as CTO, while Erin Federman with a Master's degree in Business Administration completes the management team as CCO. Prof. Kai Johnsson, Head of the Department of Chemical Biology at the Max Planck Institute for Medical Research, supports the young company with his expertise as an advisor.
Enormous market potential and benefits for the healthcare system
Therapeutic drug monitoring (TDM), for which QuantiLight has designed its solution, affects around 40 million patients worldwide. According to the company, 66% of these tests could be carried out from home. The benefits are obvious: patients save an average of 104 km of travel per test and receive their results within 15 minutes instead of days or weeks. For healthcare systems, the technology offers potential savings of up to 64%.
The company is currently in an active development phase and is looking for contacts with healthcare professionals, potential partners and investors to take the next steps towards market launch. With its user-friendly approach and clear added value for all stakeholders - patients, physicians, laboratories and healthcare systems - QuantiLight could permanently change the way medication monitoring is carried out.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of current news. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.